Puma Biotechnology grants equity awards to Douglas Hunt

PUMA BIOTECHNOLOGY, INC. executive Douglas M. Hunt reported new equity awards consisting of stock options and restricted stock units.

Rhea-AI Filing Summary

PUMA BIOTECHNOLOGY, INC. executive Douglas M. Hunt reported new equity awards consisting of stock options and restricted stock units. He was granted stock options for 70,321 shares at no exercise price shown here and 49,394 restricted stock units, both in direct ownership. These awards vest in four equal installments on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, conditioned on his continued service with the company through each vesting date.

Insider Trade Summary

Grant/Award: 119,715 shares

Grant/Award 2 txns

Insider HUNT DOUGLAS M

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,321	$0.00	$0.00
Grant/Award	Common Stock	49,394	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 70,321 contracts (Direct); Common Stock — 205,301 shares (Direct)

Footnotes (2)

1. F1. Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.
2. F2. Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Douglas M. Hunt receive from PBYI?

Douglas M. Hunt received stock options for 70,321 shares and 49,394 restricted stock units of Puma Biotechnology common stock. Both awards were granted on February 18, 2026, and are held in direct ownership according to the Form 4 disclosure.

How do Douglas M. Hunt’s new restricted stock units from PBYI vest?

The 49,394 restricted stock units vest in four equal parts. One-fourth vests on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, provided Hunt continues serving at Puma Biotechnology through each applicable vesting date.

What is the vesting schedule for Douglas M. Hunt’s new PBYI stock options?

The 70,321 Puma Biotechnology stock options vest in four equal installments. One-fourth becomes exercisable on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, contingent on Hunt’s continued service with the company on each vesting date.

Are Douglas M. Hunt’s new PBYI equity awards direct or indirect holdings?

Both the stock options and restricted stock units are reported as directly owned by Douglas M. Hunt. The Form 4 lists the ownership type and code as direct, with no intermediary entity indicated in the disclosure footnotes.

Did Douglas M. Hunt buy or sell any PBYI shares in this Form 4?

The Form 4 reflects grant or award acquisitions only. It shows two acquisition transactions coded as awards: one for stock options and one for restricted stock units, with no reported open-market purchases or sales of Puma Biotechnology common stock.

When were Douglas M. Hunt’s new PBYI equity awards granted?

Both the stock option grant and the restricted stock unit grant were dated February 18, 2026. That grant date starts the vesting schedule that runs through January 1, 2028, assuming Douglas M. Hunt remains in service with Puma Biotechnology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 08:28 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUNT DOUGLAS M

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 1700

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		A		49,394(1)	A	$0(1)	205,301	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.68	02/18/2026		A		70,321		(2)	02/17/2036	Common Stock	70,321	$0	70,321	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

2. Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

Remarks:

The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.

	/s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.